The KIT mutations did not affect the CR of inv(16) or t(8,21) AML, and the KIT mutation-related relapse risk of t(8,21) AML was significantly increased, but it was not increased in inv(16) AML, indicating that the increased relapse risk of CBF-AML may be due to the risk of t(8,21) AML but not inv(16) AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.